» Articles » PMID: 30561903

Patients with Cystic Fibrosis Having a Residual Function Mutation: Data from the Italian Registry

Overview
Date 2018 Dec 19
PMID 30561903
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: CFTR mutations permitting residual function (RF) of the CFTR protein are disease-causing. These mutations are associated with a pneumopathy that is delayed in onset and is slower in progression than are more common forms of cystic fibrosis (CF), although the disease may become severe in some patients. RF mutations are among the most frequent in Italy, thus encouraging investigation of their prevalence and associated phenotypes.

Methods: Data from the Italian Registry were used to compare patients with at least one RF mutation with those homozygous for F508del.

Results: A total of 806 patients bearing at least one RF mutation were identified among 5204 registered patients (15.5%). The RF patients were older than the F508del homozygotes (median age 26.0 years vs 19.8 years, respectively), with a higher median age at diagnosis (6.3 years vs 0.2 years, respectively) and a lower median sweat chloride value (76.0 mmol/L vs 100.0 mmol/L, respectively). In the RF group, lung infections and comorbidities were less prevalent than those in the F508del homozygotes, while better FEV and nutritional status were observed at all ages. Within the RF group, RF/F508del subjects showed more severe pneumopathy than did patients with RF/other mutations. In particular, the 3849 + 10kbC → T/F508del subjects had worse FEV and a higher prevalence of lung infections than did patients with other genotypes.

Conclusions: Patients with RF mutations are numerous in Italy and have a milder disease phenotype than do F508del homozygotes. Inside the RF group, F508del heterozygotes and, in particular, 3849 + 10kbC → T/F508del patients showed more severe pneumopathy.

Citing Articles

Variability in disease severity among cystic fibrosis patients carrying residual-function variants: data from the European Cystic Fibrosis Society Patient Registry.

Mei-Zahav M, Orenti A, Jung A, Kerem E ERJ Open Res. 2025; 11(1.

PMID: 39811546 PMC: 11726569. DOI: 10.1183/23120541.00587-2024.


Nutritional Trends in Cystic Fibrosis: Insights from the Italian Cystic Fibrosis Patient Registry.

Salvatore D, Padoan R, Amato A, Salvatore M, Campagna G, The Italian Cf Registry Working Group J Clin Med. 2024; 13(13).

PMID: 38999218 PMC: 11242145. DOI: 10.3390/jcm13133652.


Analysis of the genotypic profile and its relationship with the clinical manifestations in people with cystic fibrosis: study from a rare disease registry.

Rueda-Nieto S, Mondejar-Lopez P, Mira-Escolano M, Cutillas-Tolin A, Maceda-Roldan L, Arense-Gonzalo J Orphanet J Rare Dis. 2022; 17(1):222.

PMID: 35698092 PMC: 9195274. DOI: 10.1186/s13023-022-02373-y.


CRMS/CFSPID Subjects Carrying D1152H CFTR Variant: Can the Second Variant Be a Predictor of Disease Development?.

Terlizzi V, Padoan R, Claut L, Colombo C, Fabrizzi B, Lucarelli M Diagnostics (Basel). 2020; 10(12).

PMID: 33322690 PMC: 7764752. DOI: 10.3390/diagnostics10121080.


Extensive Gene Analysis Revealed a Higher Occurrence of Cystic Fibrosis Transmembrane Regulator-Related Disorders (CFTR-RD) among CF Carriers.

Esposito M, Aveta A, Comegna M, Cernera G, Iacotucci P, Carnovale V J Clin Med. 2020; 9(12).

PMID: 33260873 PMC: 7760778. DOI: 10.3390/jcm9123853.